Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis.
Wenzhe FanBowen ZhuShufan YueXinlin ZhengXinhua ZouFuliang LiLiangliang QiaoYanqin WuMiao XueHongyu WangYiyang TangJiaping LiPublished in: Cancer medicine (2022)
Lenvatinib plus IDADEB-TACE is well-tolerated and more effective than lenvatinib monotherapy in patients with advanced HCC.